Exelixis, Inc. $EXEL Stock Acquired by Profund Advisors LLC

Profund Advisors LLC increased its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 36.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,521 shares of the biotechnology company’s stock after purchasing an additional 11,267 shares during the period. Profund Advisors LLC’s holdings in Exelixis were worth $2,484,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Private Client Services LLC grew its holdings in Exelixis by 0.7% during the 3rd quarter. Private Client Services LLC now owns 28,539 shares of the biotechnology company’s stock valued at $1,667,000 after buying an additional 209 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Exelixis by 0.5% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 59,420 shares of the biotechnology company’s stock worth $2,549,000 after acquiring an additional 281 shares during the last quarter. Brindle & Bay Financial Advisors LLC lifted its position in shares of Exelixis by 8.0% in the third quarter. Brindle & Bay Financial Advisors LLC now owns 4,105 shares of the biotechnology company’s stock valued at $240,000 after acquiring an additional 305 shares in the last quarter. Soltis Investment Advisors LLC lifted its position in shares of Exelixis by 7.0% in the third quarter. Soltis Investment Advisors LLC now owns 4,868 shares of the biotechnology company’s stock valued at $284,000 after acquiring an additional 320 shares in the last quarter. Finally, Mather Group LLC. boosted its stake in shares of Exelixis by 124.6% during the third quarter. Mather Group LLC. now owns 757 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 420 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insider Buying and Selling

In other Exelixis news, Director Mary Beckerle sold 9,812 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $53.66, for a total transaction of $526,511.92. Following the transaction, the director owned 16,079 shares of the company’s stock, valued at $862,799.14. This trade represents a 37.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.60% of the company’s stock.

Exelixis News Summary

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations: Exelixis reported adjusted EPS of $0.94 versus the $0.89 consensus estimate and revenue of $658.7 million versus expectations of approximately $646.5 million. Revenue increased 10.2% year over year. EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales
• Positive Sentiment: CABOMETYX remained the key growth driver: U.S. net product revenue reached roughly $605 million, with franchise revenue growth of about 11% year over year, supporting confidence in Exelixis’ core commercial business.
• Positive Sentiment: Capital returns and financial strength supported sentiment: The company repurchased approximately $250 million of stock during the quarter and ended the period with about $1.4 billion in cash and marketable securities.
• Positive Sentiment: Pipeline catalyst is approaching: Exelixis outlined a March 3, 2027 FDA decision date for zanzalintinib, while continuing preparations for additional pivotal studies. Exelixis outlines March 3, 2027 PDUFA for zanza
• Positive Sentiment: TD Cowen raised its price target to $76 from $55 and assigned a Buy rating, adding to the bullish reaction following the earnings release. TD Cowen Exelixis ratings
• Neutral Sentiment: Analyst views remain mixed: Morgan Stanley raised its target to $60 but maintained Equalweight, while Truist, RBC, Barclays and other firms also lifted targets that remain below the current trading level.
• Negative Sentiment: Insider trading presents a cautionary signal: Six reported insider open-market transactions over the past six months were sales, with no purchases. This may temper enthusiasm despite the favorable quarterly results.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Wall Street Zen cut Exelixis from a “strong-buy” rating to a “buy” rating in a research report on Sunday. BMO Capital Markets restated a “market perform” rating and issued a $60.00 target price on shares of Exelixis in a report on Friday. TD Cowen raised their price target on shares of Exelixis from $55.00 to $76.00 and gave the stock a “buy” rating in a research note on Friday. Citizens Jmp lifted their price target on shares of Exelixis from $55.00 to $65.00 and gave the stock a “market outperform” rating in a report on Monday, October 19th. Finally, Royal Bank Of Canada boosted their price objective on shares of Exelixis from $51.00 to $58.00 and gave the company a “sector perform” rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $55.21.

Exelixis Price Performance

NASDAQ EXEL opened at $69.39 on Monday. The company has a market cap of $16.93 billion, a P/E ratio of 20.78, a P/E/G ratio of 1.95 and a beta of 0.45. Exelixis, Inc. has a 12 month low of $36.00 and a 12 month high of $72.10. The company has a 50-day moving average of $59.39 and a 200-day moving average of $50.92.

Exelixis (NASDAQ:EXEL) last released its earnings results on Thursday, October 29th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.05. Exelixis had a net margin of 35.45% and a return on equity of 45.54%. The business had revenue of $658.70 million for the quarter, compared to analysts’ expectations of $646.51 million. During the same period last year, the company earned $0.78 earnings per share. The company’s quarterly revenue was up 10.2% on a year-over-year basis. As a group, equities research analysts anticipate that Exelixis, Inc. will post 3.19 EPS for the current year.

Exelixis Profile

Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer and other serious diseases. The company’s research programs center primarily on targeted therapies, including treatments designed to inhibit signaling pathways involved in tumor growth and progression.

Exelixis’ lead product is CABOMETYX (cabozantinib), an oral medicine approved in the United States for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer.